Adbiotech Co. Ltd.
ADBiotech Co., Ltd. develops and sells antibodies for livestock, fisheries, and humans in South Korea and internationally. The company offers antibiotic, disinfectant, helminthic, over the counter drugs, supplementary feed, and metabolic drugs. It also offers health functional and processed foods. ADBiotech Co., Ltd. was founded in 2000 and is based in Chuncheon-si, South Korea.
Adbiotech Co. Ltd. - Asset Resilience Ratio
Adbiotech Co. Ltd. (179530) has an Asset Resilience Ratio of 22.39% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Adbiotech Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Adbiotech Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩6.16 Billion | 22.39% |
| Total Liquid Assets | ₩6.16 Billion | 22.39% |
Asset Resilience Insights
- Good Liquidity Position: Adbiotech Co. Ltd. maintains a healthy 22.39% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Adbiotech Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Adbiotech Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Adbiotech Co. Ltd. (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Adbiotech Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.28% | ₩1.68 Billion | ₩23.07 Billion | -26.23pp |
| 2023-12-31 | 33.51% | ₩9.41 Billion | ₩28.09 Billion | +5.69pp |
| 2022-12-31 | 27.81% | ₩8.63 Billion | ₩31.02 Billion | +14.55pp |
| 2021-12-31 | 13.27% | ₩2.78 Billion | ₩20.96 Billion | -1.82pp |
| 2020-12-31 | 15.09% | ₩2.84 Billion | ₩18.84 Billion | -3.62pp |
| 2019-12-31 | 18.70% | ₩2.12 Billion | ₩11.36 Billion | +3.88pp |
| 2018-12-31 | 14.83% | ₩1.44 Billion | ₩9.70 Billion | +8.75pp |
| 2017-12-31 | 6.08% | ₩635.16 Million | ₩10.45 Billion | +2.65pp |
| 2014-12-31 | 3.43% | ₩341.60 Million | ₩9.97 Billion | -- |